Juan was born in Lima, Peru and immigrated to the United States at the age of six. He is currently a MD-PhD candidate at the Perelman School of Medicine at the University of Pennsylvania. He received his bachelor’s degree in medicinal chemistry from the University of Florida and an MPhil in Chemistry at the University of Cambridge funded by the Gates Cambridge Scholarship.

After hearing Dr. Fajgenbaum speak to MD-PhD students at grand rounds, Juan decided to join the CDCN to bring new therapies to patients with refractory iMCD. He will be heading the effort to run a clinical trial using sirolimus for refractory iMCD patients. He is excited to work with the Penn Clinical Trials Office, Pfizer, and the FDA to give iMCD patients a second-line option for their treatment.